Heterogeneity of KRAS Mutation Status in Rectal Cancer

INTRODUCTION: Anti-EGFR targeted therapy is of increasing importance in advanced colorectal cancer and prior KRAS mutation testing is mandatory for therapy. However, at which occasions this should be performed is still under debate. We aimed to assess in patients with locally advanced rectal cancer...

Descripción completa

Detalles Bibliográficos
Autores principales: Jo, Peter, König, Alexander, Schirmer, Markus, Kitz, Julia, Conradi, Lena-Christin, Azizian, Azadeh, Bernhardt, Markus, Wolff, Hendrik A., Grade, Marian, Ghadimi, Michael, Ströbel, Philipp, Schildhaus, Hans-Ulrich, Gaedcke, Jochen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4827807/
https://www.ncbi.nlm.nih.gov/pubmed/27064574
http://dx.doi.org/10.1371/journal.pone.0153278

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4827807/
https://www.ncbi.nlm.nih.gov/pubmed/27064574
http://dx.doi.org/10.1371/journal.pone.0153278

Ejemplares similares